|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang K and Yuan Q: Current mechanism of
acquired resistance to epidermal growth factor receptor-tyrosine
kinase inhibitors and updated therapy strategies in human nonsmall
cell lung cancer. J Cancer Res Ther. 12:C131–C137. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shepherd FA, Rodrigues Pereira J, Ciuleanu
T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S,
Smylie M, Martins R, et al: Erlotinib in previously treated
non-small-cell lung cancer. N Engl J Med. 353:123–132. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kris MG, Natale RB, Herbst RS, Lynch TJ
Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H,
Sandler A, et al: Efficacy of gefitinib, an inhibitor of the
epidermal growth factor receptor tyrosine kinase, in symptomatic
patients with non-small cell lung cancer: A randomized trial. JAMA.
290:2149–2158. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Thatcher N, Chang A, Parikh P, Rodrigues
Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH,
Pemberton K, Archer V and Carroll K: Gefitinib plus best supportive
care in previously treated patients with refractory advanced
non-small-cell lung cancer: Results from a randomised,
placebo-controlled, multicentre study (Iressa Survival Evaluation
in Lung Cancer). Lancet. 366:1527–1537. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sequist LV, Waltman BA, Dias-Santagata D,
Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger
S, Cosper AK, et al: Genotypic and histological evolution of lung
cancers acquiring resistance to EGFR inhibitors. Sci Transl Med.
3:75ra262011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yu HA, Arcila ME, Rekhtman N, Sima CS,
Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M and Riely GJ:
Analysis of tumor specimens at the time of acquired resistance to
EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
Clin Cancer Res. 19:2240–2247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Engelman JA, Zejnullahu K, Mitsudomi T,
Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen
J, et al: MET amplification leads to gefitinib resistance in lung
cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Burroughs SK, Kaluz S, Wang D, Wang K, Van
Meir EG and Wang B: Hypoxia inducible factor pathway inhibitors as
anticancer therapeutics. Future Med Chem. 5:553–572. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wilson W and Hay M: Targeting hypoxia in
cancer therapy. Nat Rev Cancer. 11:393–410. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang GL, Jiang BH, Rue EA and Semenza GL:
Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS
heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci
USA. 92:5510–5514. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Murakami A, Takahashi F, Nurwidya F,
Kobayashi I, Minakata K, Hashimoto M, Nara T, Kato M, Tajima K,
Shimada N, et al: Hypoxia increases gefitinib-resistant lung cancer
stem cells through the activation of insulin-like growth factor 1
receptor. PLoS One. 9:864592014. View Article : Google Scholar
|
|
13
|
Morgillo F, Cascone, D'Aiuto E, Martinelli
E, Troiani T, Saintigny P, De Palma R, Heymach JV, Berrino L,
Tuccillo C and Ciardiello F: Antitumour efficacy of MEK inhibitors
in human lung cancer cells and their derivatives with acquired
resistance to different tyrosine kinase inhibitors. Br J Cancer.
105:382–392. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ko FN, Wu CC, Kuo SC, Lee FY and Teng CM:
YC-1, a novel activator of platelet guanylate cyclase. Blood.
84:4226–4233. 1994.PubMed/NCBI
|
|
15
|
Chun YS, Yeo EJ, Choi E, Teng CM, Bae JM,
Kim MS and Park JW: Inhibitory effect of YC-1 on the hypoxic
induction of erythropoietin and vascular endothelial growth factor
in Hep3B cells. Biochem Pharmacol. 61:947–954. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang L, Jiang G, Zhao X and Gong Y:
Dimethyloxalylglycine promotes bone marrow mesenchymal stem cell
osteogenesis via Rho/ROCK signaling. Cell Physiol Biochem.
39:1391–1403. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li F, Li Z, Jiang Z, Tian Y, Wang Z, Yi W
and Zhang C: Enhancement of early cardiac differentiation of
dedifferentiated fat cells by dimethyloxalylglycine via notch
signaling pathway. Am J Transl Res. 8:4791–4801. 2016.PubMed/NCBI
|
|
18
|
Rho JK, Choi YJ, Kim SY, Kim TW, Choi EK,
Yoon SJ, Park BM, Park E, Bae JH, Choi CM and Lee JC: MET and AXL
inhibitor NPS-1034 exerts efficacy against lung cancer cells
resistant to EGFR kinase inhibitors because of MET or AXL
activation. Cancer Res. 74:253–262. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu L, Nilsson MB, Saintigny P, Cascone T,
Herynk MH, Du Z, Nikolinakos PG, Yang Y, Prudkin L, Liu D, et al:
Epidermal growth factor receptor regulates MET levels and
invasiveness through hypoxia-inducible factor-1α in non-small cell
lung cancer cells. Oncogene. 29:2616–2627. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rankin EB and Giaccia AJ: The role of
hypoxia-inducible factors in tumorigenesis. Cell Death Differ.
15:678–685. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wigerup C, Påhlman S and Bexell D:
Therapeutic targeting of hypoxia and hypoxia-inducible factors in
cancer. Pharmacol Ther. 164:152–169. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Warfel NA and El-Deiry WS: HIF-1 signaling
in drug resistance to chemotherapy. Curr Med Chem. 21:3021–3028.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Harris AL: HIF-1 signaling in drug
resistance to chemotherapy. Nat Rev Cancer. 2:38–47. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Minakata K, Takahashi F, Nara T, Hashimoto
M, Tajima K, Murakami A, Nurwidya F, Yae S, Koizumi F, Moriyama H,
et al: Hypoxia induces gefitinib resistance in non-small-cell lung
cancer with both mutant and wild-type epidermal growth factor
receptors. Cancer Sci. 103:1946–1954. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang WW, Wang YB, Wang DQ, Lin Z and Sun
RJ: Integrin beta-8 (ITGB8) silencing reverses gefitinib resistance
of human hepatic cancer HepG2/G cell line. Int J Clin Exp Med.
8:3063–3071. 2015.PubMed/NCBI
|
|
26
|
El Guerrab A, Zegrour R, Nemlin CC, Vigier
F, Cayre A, Penault-Llorca F, Rossignol F and Bignon YJ:
Differential impact of EGFR-targeted therapies on hypoxia
responses: Implications for treatment sensitivity in
triple-negative metastatic breast cancer. PLoS One. 6:e250802011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Soni S and Padwad YS: HIF-1 in cancer
therapy: Two decade long story of a transcription factor. Acta
Oncol. 56:503–515. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bertout JA, Patel SA and Simon MC: The
impact of O2 availability on human cancer. Nat Rev Cancer.
8:967–975. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu F, Hu L, Ma Y, Huang B, Xiu Z, Zhang
P, Zhou K and Tang X: Increased expression of monoamine oxidase A
is associated with epithelial to mesenchymal transition and
clinicopathological features in non-small cell lung cancer. Oncol
Lett. 15:3245–3251. 2018.PubMed/NCBI
|
|
30
|
Wu D, Chen B, Cui F, He X, Wang W and Wang
M: Hypoxia-induced microRNA-301b regulates apoptosis by targeting
Bim in lung cancer. Cell Prolif. 49:476–483. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Khong TL, Thairu N, Larsen H, Dawson PM,
Kiriakidis S and Paleolog EM: Identification of the angiogenic gene
signature induced by EGF and hypoxia in colorectal cancer. BMC
Cancer. 13:5182013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC,
Kim MS and Park JW: YC-1: A potential anticancer drug targeting
hypoxia-inducible factor 1. J Natl Cancer Inst. 95:516–525. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cheng Y, Li W, Liu Y, Cheng HC, Ma J and
Qiu L: YC-1 exerts inhibitory effects on MDA-MB-468 breast cancer
cells by targeting EGFR in vitro and in vivo under normoxic
condition. Chin J Cancer. 31:248–256. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chang LC, Lin HY, Tsai MT, Chou RH, Lee
FY, Teng CM, Hsieh MT, Hung HY, Huang LJ, Yu YL and Kuo SC: YC-1
inhibits proliferation of breast cancer cells by down-regulating
EZH2 expression via activation of c-Cbl and ERK. Br J Pharmacol.
171:4010–4025. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ikezawa Y, Sakakibara-Konishi J, Mizugaki
H, Oizumi S and Nishimura M: Inhibition of Notch and HIF enhances
the antitumor effect of radiation in Notch expressing lung cancer.
Int J Clin Oncol. 22:59–69. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Moeller BJ and Dewhirst MW: HIF-1 and
tumour radiosensitivity. Br J Cancer. 95:1–5. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhen Q, Liu JF, Liu JB, Wang RF, Chu WW,
Zhang YX, Tan GL, Zhao XJ and Lv BL: Endothelial PAS
domain-containing protein 1 confers TKI-resistance by mediating
EGFR and MET pathways in non-small cell lung cancer cells. Cancer
Biol Ther. 16:549–557. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jang WJ, Jung SK, Kang JS, Jeong JW, Bae
MK, Joo SH, Park GH, Kundu JK, Hong YS and Jeong CH: Anti-tumor
activity of WK88-1, a novel geldanamycin derivative, in
gefitinib-resistant non-small cell lung cancers with Met
amplification. Cancer Sci. 105:1245–1253. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang Y, Zhang W, Wen L, Yang H, Wen M, Yun
Y, Zhao L, Zhu X, Tian L, Luo E, et al: FOXM1 confers resistance to
gefitinib in lung adenocarcinoma via a MET/AKT-dependent positive
feedback loop. Oncotarget. 7:59245–59259. 2016.PubMed/NCBI
|
|
40
|
Zhai Y, Zhang Y, Nan K and Liang X:
Reduced expression levels of PTEN are associated with decreased
sensitivity of HCC827 cells to icotinib. Oncol Lett. 13:3233–3238.
2017. View Article : Google Scholar : PubMed/NCBI
|
